Cellics Therapeutics

About:

Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines.

Website: http://cellics.com

Top Investors: CARB-X

Description:

Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines. It was created with the goal of applying Nanosponge Technology to treat and prevent diseases. It aims to employ innovative biomimetic nanomedicines to address serious diseases with a high unmet medical need. The company’s initial primary focus is on autoimmune and inflammatory diseases and difficult to treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of bacterial pneumonia. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives. The company was founded in 2014 and is headquartered in San Diego, California.

Total Funding Amount:

$36.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)cellics.com

Founders:

Liangfang Zhang

Number of Employees:

11-50

Last Funding Date:

2022-02-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai